Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.

导出原文传递

翻译打印收藏纠错

作者： Vera,Bril ^[1] ; Robert D M,Hadden ^[2] ; Thomas H,Brannagan ^[3] ; Michal,Bar ^[4] ; Elisabeth,Chroni ^[5] ; Konrad,Rejdak ^[6] ; Alberto,Rivero ^[7] ; Henning,Andersen ^[8] ; Norman,Latov ^[9] ; Todd,Levine ^[10] ; Mamatha,Pasnoor ^[11] ; Sabrina,Sacconi ^[12] ; Nizar,Souayah ^[13] ; Colin,Anderson-Smits ^[14] ; Kim,Duff ^[14] ; Erin,Greco ^[14] ; Shabbir,Hasan ^[14] ; Zhaoyang,Li ^[14] ; Leman,Yel ^[14] ; Hakan,Ay ^[14]

作者单位： The Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada. ^[1] King's College Hospital, London, UK. ^[2] Neurological Institute, Columbia University, New York City, New York, USA. ^[3] University Hospital and Faculty of Medicine, Ostrava, Czechia. ^[4] University of Patras, Rion, Greece. ^[5] Department of Neurology, Medical University of Lublin, Lublin, Poland. ^[6] Institute for Neurological Research (FLENI), Buenos Aires, Argentina. ^[7] Aarhus University, Aarhus, Denmark. ^[8] Weill Cornell Medicine, New York City, New York, USA. ^[9] CND Life Sciences, Phoenix, Arizona, USA. ^[10] The University of Kansas Medical Center, Kansas City, Kansas, USA. ^[11] University Hospital of Nice, Nice, France. ^[12] Rutgers New Jersey Medical School, Newark, New Jersey, USA. ^[13] Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA. ^[14]

关键词 ADVANCE-CIDP 1 randomized controlled trial chronic inflammatory demyelinating polyradiculoneuropathy efficacy hyaluronidase-facilitated subcutaneous immunoglobulin 10 safety